All News

Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

Kathryn H. Dao, M.D.

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

Jack Cush, MD

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.

Read Article
covid vaccine needle vaccination

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE

Md Yuzaiful Md Yusof, MRCP(UK), PhD

It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus? 

Read Article
covid coronavirus virus

More severe COVID-19 outcomes in African American, Hispanic individuals with SLE

Bella Mehta, MBBS, MS

A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Racial/ethnic disparity in U.S. lupus nephritis mortality

Janet Pope, MD, MPH, FRCPC

At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).

Read Article
ACR Best

ACR21 Best Abstracts - Day 4

Jack Cush, MD

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
Malar,rash,SLE, Lupus

Predictors of Remission and Low Disease Activity in SLE

Sheila Reyes, MD

A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus.  The goal of treatment in SLE is aimed at remission or low disease activit

Read Article
IL-35 (blood and urine) is elevated in #SLE pts with nephritis. Small study of 42 SLE pts serum IL-35 had 90% sensitivity & 65% specificity while urine IL-35 had 86.4% sensitivity and 75% specificity to establish the diagnosis of LN https://t.co/pK1rVCQQr9

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the #ACR21 annual meeting. https://t.co/SQOLQRmQtp https://t.co/ZA1uISdGyk

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE https://t.co/ihWapOaiNO https://t.co/daoIZtpsHH

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE and Health-Related Quality of Life: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #1261 presented at the #ACR21 annual meeting. https://t.co/yLPBfId6tL https://t.co/09U4nUT9c7

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more. https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Type 1 and Type II Lupus — Patient Perspectives: Dr. Mehta ( @bella_mehta) interviews Dr. Clowse about abstract #1277 presented at the #ACR21 annual meeting https://t.co/2w1Lwwhplf https://t.co/4sJR6DG0q0

Links:

Dr. John Cush RheumNow ( View Tweet)
Frailty in Lupus: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0869 presented at the #ACR21 annual meeting. https://t.co/5jR74VQBeG https://t.co/AJIhR5Waip

Links:

Dr. John Cush RheumNow ( View Tweet)
Vitamin D and Hydroxychloroquine Studies: Dr. Michelle Petri discussed studies regarding Vitamin D supplementation and as well as data on hydroxychloroquine that was presented Saturday at the #ACR21 annual meeting. https://t.co/CU8wFVYhNg

Links:

Dr. John Cush RheumNow ( View Tweet)

Hydroxychloroquine Levels in Type I and 2 Lupus: Bella Mehta ( @bella_mehta) interviews Dr. Megan Clowse about abstract #0877, presented at the #ACR21 annual meeting. https://t.co/L62iO8J9QF https://t.co/Oy58jbPPts

Links:

Dr. John Cush RheumNow ( View Tweet)
Treat to Target in SLE: Dr. Yuzaiful Yusof ( @Yuz6Yusof ) reviews abstract #0865 presented at the #ACR21 annual meeting. https://t.co/THX4nLWCaR https://t.co/951HAdkONi

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Watch: Lupus Updates: Dr. Michelle Petri Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting. https://t.co/nluRreQPT1 https://t.co/fzm1RW6Rpy

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus Day 2 Highlights: Drs Dao , Mehta, Yusof, Pope, Reyes and Castillo review lupus-related information and data presented during day 2 of the #ACR21 annual meeting. https://t.co/QX6Ay77FKo @KDAO2011 @bella_mehta @Yuz6Yusof @Janetbirdope @RHEUMarampa @_Castillo_Pedro https://t.co/ldAHqXsi0G

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR21 The Great Debate: Belimumab vs Voclosporin as Add-On Therapy in #LupusNephritis | Dr. Petri & Dr. Rovin Audience Vote 🗳: What would you add to mycophenolate first? Belimumab 71%, Voclosporin 29% #ACRAmbassador @ACRheum Summary of Pros & Cons of Each⬇️ https://t.co/OtLxs8IYr9
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×